Hetero Drugs Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Hetero Drugs Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3477
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Hetero Drugs Ltd (Hetero) is a manufacturer of active pharmaceutical ingredients, intermediate chemicals and finished dosages. The company specializes in process chemistry, API manufacturing, formulation development, manufacturing and commercialization of bio-generics, and also offers custom research and manufacturing services to global biotechnology and pharmaceutical companies. Hetero offers products in various therapeutic areas which include HIV/AIDS, oncology, cardiovascular, neurology and hepatitis, among others. The company conducts research and development to develop new products. It markets its products through a network of marketing offices across the world. Hetero is headquartered in Hyderabad, Telangana, India.

Hetero Drugs Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hetero Drugs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 11
Kadmon Amends Supply And Distribution Agreement with Camber Pharma 12
Stada Arzneimittel to Form Joint Venture with Hetero Drugs 13
Cipla Enters into Co-Marketing Agreement with Hetero Drugs 14
Furen Pharma to Form JV with Hetero Drugs for Oncology and AIDS 15
DFH Pharma Enters Into R&D Agreement With Hetero For HIV Drugs 16
Hetero Drugs Forms Joint Venture With Neopharma 17
Licensing Agreements 18
Hetero Enters into Licensing Agreement with VIVUS for STENDRA 18
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 19
Hetero Labs Enters into Licensing Agreement with Medicines Patent Pool 20
Hetero Labs Enters into Licensing Agreement with Medicines Patent Pool 21
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 22
Dr Reddy’s Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 24
Gilead Sciences Enters into Licensing Agreement with Hetero Labs 25
Hetero Drugs Ltd – Key Competitors 26
Hetero Drugs Ltd – Key Employees 27
Hetero Drugs Ltd – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Joint Venture 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hetero Drugs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hetero Drugs Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 11
Kadmon Amends Supply And Distribution Agreement with Camber Pharma 12
Stada Arzneimittel to Form Joint Venture with Hetero Drugs 13
Cipla Enters into Co-Marketing Agreement with Hetero Drugs 14
Furen Pharma to Form JV with Hetero Drugs for Oncology and AIDS 15
DFH Pharma Enters Into R&D Agreement With Hetero For HIV Drugs 16
Hetero Drugs Forms Joint Venture With Neopharma 17
Hetero Enters into Licensing Agreement with VIVUS for STENDRA 18
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 19
Hetero Labs Enters into Licensing Agreement with Medicines Patent Pool 20
Hetero Labs Enters into Licensing Agreement with Medicines Patent Pool 21
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 22
Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 24
Gilead Sciences Enters into Licensing Agreement with Hetero Labs 25
Hetero Drugs Ltd, Key Competitors 26
Hetero Drugs Ltd, Key Employees 27
Hetero Drugs Ltd, Other Locations 28
Hetero Drugs Ltd, Subsidiaries 28
Hetero Drugs Ltd, Joint Venture 29

List of Figures
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hetero Drugs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Hetero Drugs Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Twist Bioscience Corp (TWST):製薬・医療:M&Aディール及び事業提携情報
    Summary Twist Bioscience Corp (Twist Bioscience) is a provider of synthetic DNA Tools. Its silicon-based DNA synthesis platform enables precise synthesis and sequencing process and production of synthetic DNA tools. The company offers its products which include DNA tools for gRNA cloning such as una …
  • The Menarini Group:企業のM&A・事業提携・投資動向
    The Menarini Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Menarini Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Toho Holdings Co Ltd (8129):企業の財務・戦略的SWOT分析
    Toho Holdings Co Ltd (8129) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Liberty Star Uranium & Metals Corp (LBSR):企業の財務・戦略的SWOT分析
    Summary Liberty Star Uranium & Metals Corp (Liberty Star), formerly Liberty Star Gold Corp is a mining and mineral exploration and development company that offers mineral resources. The company offers acquisition, exploration, operations, management, mining, production, and development of gold, copp …
  • Immatics Biotechnologies GmbH:企業の戦略的SWOT分析
    Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Proteon Therapeutics Inc (PRTO):製薬・医療:M&Aディール及び事業提携情報
    Summary Proteon Therapeutics Inc (Proteon Therapeutics) is a late-stage biopharmaceutical company that develops pharmaceutical products for the treatment of renal and vascular diseases. The company develops investigational therapies to treat hemodialysis and peripheral artery disease patients. Its p …
  • Davide Campari-Milano S.p.A.:戦略・SWOT・企業財務分析
    Davide Campari-Milano S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Davide Campari-Milano S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Avid Technology Inc (AVID):企業の財務・戦略的SWOT分析
    Avid Technology Inc (AVID) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • The Walt Disney Company (DIS):企業の財務・戦略的SWOT分析
    The Walt Disney Company (DIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Sunbelt Transformer Ltd:電力:M&Aディール及び事業提携情報
    Summary Sunbelt Transformer Ltd (Sunbelt Transformer) is a provider of new and reconditioned transformers and electrical equipment for commercial and industrial markets. The company’s products include padmount transformers, substation transformers, dry-type transformers, pole-mount transformers, mot …
  • Clarient Inc-医療機器分野:企業M&A・提携分析
    Summary Clarient Inc (Clarient) is a cancer diagnostic laboratory services provider that provides comprehensive cancer–diagnostic laboratory services. The company provides oncology testing and other diagnostics services. Clarient offers detailed information to characterize and assess cancer for accu …
  • CIBC Wealth Management:企業の戦略・SWOT・財務情報
    CIBC Wealth Management - Strategy, SWOT and Corporate Finance Report Summary CIBC Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • NBN Co Ltd:企業の戦略的SWOT分析
    NBN Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Energizer Holdings, Inc.:企業の戦略・SWOT・財務情報
    Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Pt Pioneerindo Gourmet International Tbk:企業の戦略・SWOT・財務分析
    Pt Pioneerindo Gourmet International Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Pioneerindo Gourmet International Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Orix Corporation:企業の戦略・SWOT・財務分析
    Orix Corporation - Strategy, SWOT and Corporate Finance Report Summary Orix Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • International Dairy Queen, Inc.:企業の戦略・SWOT・財務情報
    International Dairy Queen, Inc. - Strategy, SWOT and Corporate Finance Report Summary International Dairy Queen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Wentworth Resources Ltd (WRL):企業の財務・戦略的SWOT分析
    Wentworth Resources Ltd (WRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • KineMed Inc-製薬・医療分野:企業M&A・提携分析
    Summary KineMed Inc (KineMed) is a biotechnology company that develops and commercializes proprietary biomarker platform technology. The company applies its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs …
  • Driver Group Plc (DRV):企業の財務・戦略的SWOT分析
    Driver Group Plc (DRV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆